22:58 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

Two faces of FOXO1

Columbia University and AstraZeneca plc (LSE:AZN; NYSE:AZN) have identified the first FOXO1 inhibitors that can selectively block the transcription factor’s glucose-stimulating activity without inducing lipogenesis. Optimization of the compounds could yield a therapy for Type...
07:00 , Jun 24, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Breast cancer SIN3 homolog A transcription regulator (SIN3A) In vitro and mouse studies suggest that blocking interactions between SIN3A and its target transcription factors...